The secondary anti-inflammatory/immunomodulating effects of the AMPK activator metformin may enable drug repurposing and expansion of available therapeutic options for a series of chronic rheumatologic disorders, particularly RA. This evidence concerns the gene PRKAA1 and rheumatoid arthritis.